Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade.
To understand the role of the renin-angiotensin-aldosterone system in the pathogenesis of human hypertension, in serial studies we have blocked the system using three different pharmacologic probes: 1) reduction of renin secretion by administration of the beta receptor blocker, propranolol; 2) blockade of the action of angiotensin II by infusion of saralasin, a competitive antagonist of angiotensin II; and 3) blockade of the enzymatic conversion of angiotensin I to angiotensin II by infusing a nonapeptide competitive inhibitor. The depressor responses induced by either propranolol or the nonapeptide expose a significant to major involvement of excess renin--angiotensin in maintaining the hypertension of some 50 to 70% of common forms of hypertension including "essential" hypertension. This subgroup includes nearly all patients with high or "normal" renin--sodium profiles. The considerably lower estimates for a renin factor in essential hypertension suggested by saralasin testing now appear due to the partial agonism of this drug. Further studies are required to determine whether this relative or absolute excess of renin secretion is primarily involved in the hypertension and if not why it fails to shut itself off. Similar studies of normal subjects are also needed to determine whether renin support of blood pressure is proportionately greater or less than in hypertensive subjects. Meanwhile the validation provided by these three different pharmacologic probes portends a burgeoning clinical role for renin--sodium profiling not only in screening for renal and adrenal cortical hypertensions but also for characterizing the vasoconstrictor and volume elements involved in various individual patients and thus enabling more specific treatments of the various subtypes of essential hypertension.
D000450:Aldosterone / Q000502:physiology; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure; D001810:Blood Volume; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008954:Models, Biological; D009318:Natriuresis; D009842:Oligopeptides / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology* / Q000627:therapeutic use; D012504:Saralasin / Q000494:pharmacology / Q000627:therapeutic use; D013722:Teprotide / Q000494:pharmacology* / Q000627:therapeutic use; D014655:Vascular Resistance; D000092502:Renin Inhibitors
D000450:Aldosterone; D000804:Angiotensin II; D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D011433:Propranolol; D012504:Saralasin; D013722:Teprotide; D000092502:Renin Inhibitors